Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh C. Buyukkaramikli; Saskia de Groot; Rob Riemsma; Debra Fayter; Nigel Armstrong; Piet Portegijs; Steven Duffy; Jos Kleijnen; Maiwenn J. Al

doi:10.1007/s40273-018-0708-4

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh C. Buyukkaramikli^*, Saskia de Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen, Maiwenn J. Al

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Pages (from-to)	141-153
Number of pages	13
Journal	Pharmacoeconomics
Volume	37
Issue number	2
DOIs	https://doi.org/10.1007/s40273-018-0708-4
Publication status	Published - Feb 2019

Keywords

1ST-LINE TREATMENT
ENDOCRINE THERAPY
LETROZOLE
BEVACIZUMAB
PALBOCICLIB
UTILITY

Cite this

Buyukkaramikli, N. C., de Groot, S., Riemsma, R., Fayter, D., Armstrong, N., Portegijs, P., Duffy, S., Kleijnen, J., & Al, M. J. (2019). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 37(2), 141-153. https://doi.org/10.1007/s40273-018-0708-4

Buyukkaramikli, Nasuh C. ; de Groot, Saskia ; Riemsma, Rob ; Fayter, Debra ; Armstrong, Nigel ; Portegijs, Piet ; Duffy, Steven ; Kleijnen, Jos ; Al, Maiwenn J. / Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2019 ; Vol. 37, No. 2. pp. 141-153.

@article{916cbfa854c7419fb28cc7f78cc99b8d,

title = "Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

keywords = "1ST-LINE TREATMENT, ENDOCRINE THERAPY, LETROZOLE, BEVACIZUMAB, PALBOCICLIB, UTILITY",

author = "Buyukkaramikli, {Nasuh C.} and {de Groot}, Saskia and Rob Riemsma and Debra Fayter and Nigel Armstrong and Piet Portegijs and Steven Duffy and Jos Kleijnen and Al, {Maiwenn J.}",

year = "2019",

month = feb

doi = "10.1007/s40273-018-0708-4",

language = "English",

volume = "37",

pages = "141--153",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "2",

}

Buyukkaramikli, NC, de Groot, S, Riemsma, R, Fayter, D, Armstrong, N, Portegijs, P, Duffy, S, Kleijnen, J & Al, MJ 2019, 'Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 37, no. 2, pp. 141-153. https://doi.org/10.1007/s40273-018-0708-4

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Buyukkaramikli, Nasuh C.; de Groot, Saskia; Riemsma, Rob; Fayter, Debra; Armstrong, Nigel; Portegijs, Piet; Duffy, Steven; Kleijnen, Jos; Al, Maiwenn J.

In: Pharmacoeconomics, Vol. 37, No. 2, 02.2019, p. 141-153.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Buyukkaramikli, Nasuh C.

AU - de Groot, Saskia

AU - Riemsma, Rob

AU - Fayter, Debra

AU - Armstrong, Nigel

AU - Portegijs, Piet

AU - Duffy, Steven

AU - Kleijnen, Jos

AU - Al, Maiwenn J.

PY - 2019/2

Y1 - 2019/2

KW - 1ST-LINE TREATMENT

KW - ENDOCRINE THERAPY

KW - LETROZOLE

KW - BEVACIZUMAB

KW - PALBOCICLIB

KW - UTILITY

U2 - 10.1007/s40273-018-0708-4

DO - 10.1007/s40273-018-0708-4

M3 - Review article

VL - 37

SP - 141

EP - 153

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 2

ER -

Buyukkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P et al. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019 Feb;37(2):141-153. https://doi.org/10.1007/s40273-018-0708-4

Access to Document

10.1007/s40273-018-0708-4